Chronic Kidney Disease Market Outlook:
Chronic Kidney Disease Market size was valued at USD 62.64 billion in 2025 and is expected to reach USD 107 billion by 2035, expanding at around 5.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of chronic kidney disease is assessed at USD 65.74 billion.
The chronic kidney disease market is witnessing steady growth as the prevalence of CKD rises globally, driven by increasing rates of diabetes, hypertension, and aging populations. Furthermore, the demand for early diagnostic tools and effective treatments is expanding as healthcare providers seek to mitigate disease progression and improve patient outcomes. In July 2023, the European Commission granted approval to Boehringer Ingelheim and Eli Lilly for Jardiance, a drug used to treat chronic kidney disease, further underpinning industry interest in new treatments. Governments and health organizations are also boosting their efforts toward tackling CKD through public awareness campaigns and ensuring better access to its treatment for patients, thus indicating a growth trajectory for the chronic kidney disease market.
Governments worldwide are prioritizing chronic kidney disease care, with initiatives that emphasize early diagnosis and management to reduce the economic and health burden of the disease. In 2023, the diagnosed cases of CKD in the U.S. were reported to stand at 5 million and are likely to increase. In addition, North America and Europe fund research gives access to innovative treatments, further pushing the market. The increasing prevalence of chronic kidney disease, coupled with proactive intervention through governments, opens lucrative growth opportunities for players in the chronic kidney disease market.
